Want to see CTKB full AI Analyst Report?
Top Page
Cytek Biosciences
(NASDAQ:CTKB)
Select Model
Select Model
Rating:55Neutral
Price Target:
$5.00
▲(12.11% Upside)
Action:Reiterated
Date:08/24/26
The score is primarily held back by deteriorating profitability and negative cash flow despite strong revenue growth and a low-debt balance sheet. Technical momentum is supportive and guidance was modestly improved, but a negative P/E (loss-making) and the patent-case damages uncertainty cap the overall rating.
Positive Factors
Growing Installed Base and Recurring Revenue
The expanding installed base creates a durable foundation for reagent, consumable, software and service demand. Recurring revenue growth increases customer lifetime value and should make future revenue less dependent on laboratory capital-equipment cycles.
Negative Factors
Persistent Losses and Negative Cash Flow
The reversal from positive prior-year cash generation to operating and free-cash-flow burn indicates weak operating leverage and raises funding risk if sustained. Deep losses also limit the company’s ability to self-finance expansion despite its cash reserves.
Read all positive and negative factors
Positive Factors
Negative Factors
Growing Installed Base and Recurring Revenue
The expanding installed base creates a durable foundation for reagent, consumable, software and service demand. Recurring revenue growth increases customer lifetime value and should make future revenue less dependent on laboratory capital-equipment cycles.
Read all positive factors
Cytek Biosciences (CTKB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$594.02M
Dividend YieldN/A
Average Volume (3M)1.73M
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue Growth5.44%
EPS Growth-1130.00%
CountryUS
Employees682
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.62
Shares Outstanding129,983,250
10 Day Avg. Volume768,350
30 Day Avg. Volume1,731,532
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.89
Price to Sales (P/S)3.20
P/FCF Ratio-73.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside34.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$208.83M
Cytek Biosciences Business Overview & Revenue Model
Company Description
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Light...
How the Company Makes Money
Cytek primarily generates revenue by selling flow cytometry instruments (capital equipment) and then monetizing the installed base through recurring, higher-frequency purchases tied to instrument usage and ownership. Key revenue streams include: (...
Cytek Biosciences Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Neutral
The call presents a mixed but cautiously constructive picture: revenue growth (6% YoY) driven by strong performance in the U.S. and China, expansion of installed base, growing recurring revenue (35% of LTM), and strategic product launches (Borealis and Aurora Evo) underpin future upside. Offsetting these positives are widening GAAP losses, a Q2 adjusted EBITDA decline, regional weaknesses in EMEA and parts of APAC, rising operating expenses (including litigation-related G&A increases), and some one-time items (tariff refund, investment write-off) that cloud margin comparability. Management raised the low end of guidance and expects H2 improvement, but several challenges (regional budgetary pressures, delayed clinical penetration in the U.S., and reorganization timeline) temper near-term outlook.Positive Updates
Quarterly Revenue Growth
Q2 2026 revenue of $48.1 million, up 6% year-over-year (compared to $45.6M in Q2 2025).
Negative Updates
Widening GAAP Net Loss
GAAP net loss of $12.2 million in Q2 2026 versus $5.6 million in Q2 2025, reflecting higher operating loss, lower other income, and a tax expense versus prior year tax benefit.
Read all updates
Q2-2026 Updates
Positive
Negative
Quarterly Revenue Growth
Q2 2026 revenue of $48.1 million, up 6% year-over-year (compared to $45.6M in Q2 2025).
Read all positive updates
Company Guidance
Cytek raised the low end of its full‑year 2026 revenue guidance to $207–$212 million (midpoint up $1 million) assuming no change in currency rates and said revenue should be significantly higher in Q4 versus Q3 per normal seasonality; management expects adjusted EBITDA to be roughly break‑even for 2026 with improvement in H2 after a Q2 adjusted EBITDA loss of $1.5 million (Q2 GAAP net loss $12.2 million), Q2 revenue was $48.1 million (+6% YoY), and free cash flow was approximately neutral. They said gross margins (excluding a $2.8 million tariff refund) should increase as revenue rises—Q2 GAAP gross margin was 59% (53% excl. refund), adjusted gross margin was 61% (56% excl. refund), product margin was 60% (52% excl. refund) and service margin was 56%—cash and marketable securities totaled $262 million as of June 30, 2026, and recurring revenue represented 35% of trailing 12‑month revenue.Cytek Biosciences Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 206.71M | 201.49M | 200.45M | 193.01M | 164.04M | 127.95M |
| Gross Profit | 110.03M | 104.46M | 111.11M | 109.43M | 100.97M | 79.14M |
| EBITDA | -27.15M | -17.39M | 4.79M | -4.41M | 9.49M | 8.92M |
| Net Income | -80.58M | -66.54M | -6.02M | -12.15M | 2.58M | 3.00M |
Balance Sheet | ||||||
| Total Assets | 446.93M | 461.54M | 499.50M | 494.46M | 519.48M | 463.31M |
| Cash, Cash Equivalents and Short-Term Investments | 262.00M | 261.53M | 277.86M | 262.41M | 341.15M | 364.62M |
| Total Debt | 26.46M | 23.74M | 17.02M | 14.14M | 18.09M | 0.00 |
| Total Liabilities | 124.98M | 119.80M | 103.76M | 101.39M | 93.93M | 57.92M |
| Stockholders Equity | 321.95M | 341.74M | 395.74M | 393.06M | 425.30M | 405.04M |
Cash Flow | ||||||
| Free Cash Flow | -12.08M | -8.77M | 21.85M | 454.00K | -22.10M | 266.00K |
| Operating Cash Flow | -6.04M | -4.69M | 25.38M | 5.28M | -12.23M | 4.63M |
| Investing Cash Flow | -2.98M | 10.12M | -82.97M | -93.89M | -55.91M | -20.99M |
| Financing Cash Flow | 3.88M | -13.43M | -15.82M | -41.81M | 5.51M | 213.56M |
Cytek Biosciences Technical Analysis
Positive
4.46
Price Trends
4.47
Positive
4.37
Positive
4.62
Negative
Market Momentum
0.05
Positive
50.72
Neutral
37.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTKB, the sentiment is Positive. The current price of 4.46 is below the 20-day moving average (MA) of 4.53, below the 50-day MA of 4.47, and below the 200-day MA of 4.62, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 50.72 is Neutral, neither overbought nor oversold. The STOCH value of 37.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTKB.
Cytek Biosciences Risk Analysis
Cytek Biosciences disclosed 73 risk factors in its most recent earnings report. Cytek Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cytek Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $1.17B | 17.16 | 28.39% | ― | 3.14% | ― | |
63 Neutral | $870.82M | -56.50 | -8.23% | ― | 15.30% | 40.66% | |
62 Neutral | $2.34B | -30.13 | -38.36% | ― | 28.14% | -5.15% | |
59 Neutral | $778.90M | 35.22 | 4.60% | ― | 5.31% | ― | |
55 Neutral | $594.02M | -7.42 | -23.53% | ― | 5.44% | -1130.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $484.90M | -3.60 | -4961.74% | ― | 2.02% | 75.85% |
* Healthcare Sector Average
CTKB
Cytek Biosciences
4.62
0.45
10.79%
PACB
Pacific Biosciences
1.55
0.22
16.54%
VREX
Varex Imaging
18.49
7.02
61.20%
SIBN
SI-Bone
19.20
2.58
15.52%
BFLY
Butterfly Network
8.72
7.09
434.97%
BVS
Bioventus
13.79
6.54
90.21%
Cytek Biosciences Corporate Events
Business Operations and StrategyLegal Proceedings
Cytek Biosciences Faces Mixed Jury Verdict in Patent Case
Negative
Aug 24, 2026
On August 21, 2026, Cytek Biosciences reported that a Delaware federal jury returned a mixed verdict in a patent infringement case brought by Beckman Coulter, Inc. The jury found in Cytek’s favor on three of four asserted patent claims, ruli...
Executive/Board Changes
Cytek Biosciences Announces Chief Legal Officer Transition
Neutral
Jun 25, 2026
Cytek Biosciences, Inc. announced that Chief Legal Officer and Corporate Secretary Valerie Barnett will leave her position effective June 29, 2026, following a mutual agreement reached on June 18, 2026. The company emphasized that Barnett’s ...
Executive/Board ChangesShareholder Meetings
Cytek Biosciences Stockholders Back Board, Pay and Auditor
Positive
Jun 16, 2026
On June 10, 2026, Cytek Biosciences, Inc. held its 2026 annual meeting of stockholders, with approximately 86.1% of outstanding common shares represented, reflecting strong investor engagement in the company’s corporate governance. Stockhold...
Executive/Board Changes
Cytek Biosciences Announces Resignation of Senior Sales Executive
Neutral
Jun 2, 2026
On May 27, 2026, Cytek Biosciences, Inc. announced that Philippe Busque, Ph.D., submitted his resignation as Senior Vice President, Global Sales and Services, effective June 5, 2026. The departure, which the company said is to allow him to pursue ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.